[{"id":"6cc48963-0e06-49f2-9b2f-37053bca848e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04669002","created_at":"2021-01-19T20:44:14.044Z","updated_at":"2024-07-02T16:35:41.238Z","phase":"Phase 2","brief_title":"EP0057 in Combination With Olaparib in Advanced Ovarian Cancer","source_id_and_acronym":"NCT04669002","lead_sponsor":"Ellipses Pharma","biomarkers":" HRD • BRCA","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • irinotecan • davamotecan pegadexamer (EP0057)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 12/14/2020","start_date":" 12/14/2020","primary_txt":" Primary completion: 02/17/2023","primary_completion_date":" 02/17/2023","study_txt":" Completion: 05/05/2023","study_completion_date":" 05/05/2023","last_update_posted":"2023-08-02"},{"id":"31cd42bd-2aac-4afa-811c-51661bcc2afe","acronym":"","url":"https://clinicaltrials.gov/study/NCT05411679","created_at":"2022-06-09T13:55:28.993Z","updated_at":"2024-07-02T16:35:45.971Z","phase":"Phase 2","brief_title":"EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer","source_id_and_acronym":"NCT05411679","lead_sponsor":"Ellipses Pharma","biomarkers":" PD-L1 • ATM","pipe":" | ","alterations":" ATM expression","tags":["PD-L1 • ATM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • davamotecan pegadexamer (EP0057)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-06-12"},{"id":"96c10afe-5c80-4248-8fc9-fdf79cd07434","acronym":"","url":"https://clinicaltrials.gov/study/NCT01625936","created_at":"2021-01-18T06:58:44.377Z","updated_at":"2024-07-02T16:37:07.364Z","phase":"Phase 1b","brief_title":"CRLX101 Plus Bevacizumab in Advanced RCC","source_id_and_acronym":"NCT01625936","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • davamotecan pegadexamer (EP0057)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 07/01/2017","primary_completion_date":" 07/01/2017","study_txt":" Completion: 07/16/2018","study_completion_date":" 07/16/2018","last_update_posted":"2018-08-29"}]